IXHL Incannex Healthcare Limited - ADR
1,212
$2.78
$0.08
(2.96%)
| Watchers | 1,212 |
| 52-Wk Low | $1.96 |
| 52-Wk High | $12.68 |
| Market Cap | $44.12M |
| Volume | 12.00 |
| 52-Wk High | $12.68 |
| 52-Wk Low | $1.96 |
FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use DisorderBenzinga • 21 days ago
Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug...
Share to Feed
Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 208,200...
Appendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for Anxiety
Figure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best...
MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Highlights: Clarion's Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant...
MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), ('Incannex' or the 'Company'), a pharmaceutical company developing novel medicinal...
Highlights: 72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia.Topline results from the trial anticipated within current Q1 2024.FDA IND application is...
MELBOURNE, AustraliaandNEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), ('Incannex' or the 'Company'), a pharmaceutical company developing unique...